Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in H

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant KEYTRUDA, Merck’s anti...

Related Keywords

United States , Canada , American , Peter Dannenbaum , Damini Chokshi , Melissa Moody , New England Journal , Additional Data From , Combined Positive Score , Triple Negative Breast Cancer , African American , Neck Squamous Cell , Bacillus Calmette Guerin , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Important Safety Information , Fatal Immune Mediated Adverse ,